RUNX2 and breast cancer: We suggest that miR-218 loaded ADMSC-exosomes may be an effective anti-metastatic and anti-angiogenic treatment in breast cancer in part through targeting Runx2 and Rictor. However, this study has its own limitations, including the lack of an animal model and confirmation of gene expression data in protein level.